Home » ThromboGenics Begins Development of Anti-VPAC Antibody
ThromboGenics Begins Development of Anti-VPAC Antibody
Belgian biotechnology company ThromboGenics will continue the development of its anti-Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase Activating Peptide Receptor-1 (VPAC) antibody for the treatment of thrombocytopenia.
Thrombocytopenia, the reduced number of platelets in blood, is a common severe side effect of chemotherapy and increases the risk of bleeding and severity of hemorrhage.
The company worked with researchers at the University of Leuven in Belgium to develop this therapeutic approach to stimulate the production of platelets, ThromboGenics said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May